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Abstract
The increased use of cardiac rhythm management devices has led to an increase in cardiac
device-related infections (CDI). Staphylococcus aureus and epidermidis account for the vast
majority of CDI. CDI due to rapidly growing non-tuberculous mycobacteria is very rare, with
only about ten cases having been reported. We report a case of pacemaker pocket infection with
Mycobacterium phlei. There are only three published reports of human infection involving
this typically non-pathogenic organism. To the best of our knowledge, this is the first report of
CDI with Mycobacterium phlei. (Cardiol J 2011; 18, 6: 687–690)
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Introduction
Expanding clinical indications and the growing
burden of cardiovascular disease has led to in-
creased implantation of cardiac rhythm manage-
ment devices (CRMD) which include permanent
pacemakers, implantable cardioverter defibrillators
and cardiac resynchronization therapy (CRT) devi-
ces [1, 2]. Between 1996 and 2003, implantation of
CRMD increased by about 50% in the United States
[3]. This was associated with a three-fold increase
in hospitalization for cardiac device-related infec-
tions (CDI) [3]. Staphylococcus aureus and epider-
midis account for the vast majority of CDI [3]. CDI
due to non-tuberculous mycobacteria (NTM) is ex-
tremely rare, with only about ten reported cases [4].
We report a case of pacemaker pocket infection with
Mycobacterium phlei. To the best of our knowledge,
there are only three published reports of human
infection involving this organism, and no prior re-
ports of CDI [5–7].
Case report
A 73 year-old female with ischemic cardiomyo-
pathy underwent implantation of a cardiac resyn-
chronization therapy-defibrillator (CRT-D) device
for NYHA class III heart failure. Medical history
included diabetes, hypertension, prior anterior wall
myocardial infarction, and coronary stent place-
ment. Left ventricular ejection fraction was 30–35%,
and QRS duration was 130 ms with left bundle
branch block morphology. Medications included
metoprolol succinate, lisinopril, aspirin, glipizide
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and furosemide. A CRT-D generator was placed in
the left pectoral area and the leads were positioned
in the right atrium and right ventricular septum by
active fixation mechanism. The left ventricular pac-
ing lead was positioned in the postero-lateral branch
of the coronary sinus. Standard techniques were
used and appropriate position and adequate pacing
and capture thresholds of all leads were confirmed.
The patient had a small post-operative hematoma
which resolved over the following two weeks. The
device was set to DDDR mode, VT and VF zones
were programmed at 171 and 200 respectively.
Post-operatively, she was started on warfarin as
multiple episodes of paroxysmal atrial fibrillation
(AF) were noted on device monitoring. Two weeks
later, amiodarone was started following an inappro-
priate shock due to AF with rapid ventricular re-
sponse. At one-month follow up, some serosan-
guinous discharge was noted at the pocket site.
There was no local erythema, swelling, or tender-
ness and a small amount of fluid could be expressed
from the medial aspect of the pocket. She was ad-
mitted to the hospital and treated empirically with
intravenous vancomycin for presumed pocket infec-
tion. Blood cell counts were normal, blood and swab
cultures remained sterile. Therefore, vancomycin
was discontinued and the patient was discharged on
oral minocycline. Two weeks later, a small fluid col-
lection with surrounding erythema and induration
was noted at the medial aspect of the pocket. She
was readmitted, cultures were repeated, and intra-
venous vancomycin was restarted. She remained
afebrile and WBC count was 9,500/mm3. Explora-
tion of the pocket site revealed a small amount of
pus below the skin with communication to the pace-
maker pocket. The device and leads were explant-
ed and the pocket was thoroughly debrided. The pus
was sent for microbiological analysis including acid
fast bacilli (AFB) smear, Gram stain, fungal, aerobic
and anaerobic cultures. On microscopy, rare beaded
Gram positive bacilli, weakly positive on modified
AFB (Kinyoun) stain were noted (Figs. 1–3).
The infectious disease team was consulted and tri-
methoprim/sulfamethoxazole was added to cover for
infection with Nocardia. Blood cultures remained
sterile but fluid cultures yielded a moderate amount
of mycobacteria. DNA sequencing confirmed the
organism to be Mycobacterium phlei. It was suscep-
tible to amikacin, clarithromycin, doxycycline, mi-
nocycline, and trimethoprin/sulfamethoxazole. Van-
comycin was discontinued and doxycycline was ad-
ded to the antibiotic regimen. Due to the indolent
nature of the infection, we recommended prolonged
antibiotic therapy for 12 months. Four weeks after
Figure 3. Modified Kinyoun’s acid-fast stain of the case iso-
late showing sheets of acid-fast positive (pink) rods (400×).
Modified AFB stain has a weaker decolorization step.
Figure 1. Gram stain of the case isolate (400×). Note
the weakly staining gram positive rods with occasional
beaded morphology (arrow).
Figure 2. Routine Kinyoun acid-fast stain of the case
isolate (400×). Note the sheets of acid-fast negative
(blue) rods. Rapidly growing mycobacteria often stain
negative by the routine AFB stain.
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explantation, the patient underwent right sided
CRT-D device implantation without complications.
At six month follow-up, she remains asymptomatic
on dual antibiotics and free of infection.
Discussion
Non-tuberculous mycobacteria are ubiquitous
organisms that are found widely in the environment
including tap water and soil [8]. Cardiac device
related infection due to NTM is extremely rare with
only about ten reported cases. The majority of these
are caused by rapidly growing NTM, of which My-
cobacterium fortuitum is the commonest [4]. M. phlei
is a rapidly growing NTM which is typically non-
-pathogenic with only three reported cases of human
infection [5–7]. There have been numerous reports
of hospital/health care-associated infections with
NTM, ranging from sternal wound infections follow-
ing cardiac surgery, ocular infections following
LASIK (laser-assisted in situ keratomileusis), and
skin infections following plastic surgery to abscess-
es after intramuscular injections [8–10]. Though
individual susceptibility is likely to be a crucial
factor, specific clinical risk factors for infection
with NTM have not been identified. Advanced age
and the presence of diabetes in our patient are
known risk factors for post-operative infections in
general. However, given the rarity of NTM-rela-
ted infections, it is unlikely that diabetes or age is
a major factor determining susceptibility to these
infections. Colonization of aqueous solutions used
to mark the incision site before surgery and in hos-
pital water systems has been incriminated in pre-
vious nosocomial outbreaks and is the only known
risk factor [8––10]. In our case, no definite hospital
source of infection was identified despite an exten-
sive environmental investigation (including a re-
view of surveillance cultures) by the infection con-
trol team. Furthermore, it is known that NTM have
intermediate/high resistance to antiseptics and dis-
infectant due to the high lipid content and triple
layered structure of their cell wall. However, glu-
taraldehyde and alcohol are effective, provided
sufficient contact time is allowed. At implantation,
a combination of chlorehexidine (2%) and iso-
-propyl alcohol (70%) was used in our patient. In-
terestingly, our patient was an avid fisher and had
extensive aquatic contact. Whether this led to
colonization of her skin with NTM and subsequent
infection is unknown. Though some atypical my-
cobacterial infections like those related to M. mari-
num are known to be associated with aquatic
contact, such an association has not been repor-
ted with M. phlei.
Diagnosis of NTM-related infections is difficult
and often delayed as conventional microbiologic
tests are inadequate [10]. The mean time to diag-
nosis in prior cases was approximately 34 days [4].
On Gram stain, NTM appear as Gram-positive ba-
cilli and can be mistaken for Nocardia, Rhodococcus
or Corneybacterium. Despite positive cultures, iden-
tification of specific species of NTM using traditio-
nal biochemical and phenotypic methods is difficult
and genetic/molecular diagnostics like nucleic acid
probes or PCR-restriction enzyme analysis are usu-
ally necessary. For CDI in general, current guide-
lines recommend complete hardware removal in the
presence of blood stream or pocket infection. The
duration of antibiotic therapy and optimal time of
re-implantation are individualized based on the viru-
lence of the causative organism and presence or
absence of bacteremia, endocarditis etc. [11]. Due
to the rarity of NTM-related CDI, there are no clear
management guidelines as to the duration of thera-
py. Based on prior reports, a combination therapy
of two or three drugs for six to 12 months appears
necessary. The choice of antibiotics depends on the
results of susceptibility testing.
Conclusions
This case highlights the growing concern over
cardiac device infections with uncommon and fas-
tidious organisms such as NTM. There is a poten-
tial for delay in diagnosis due to the rarity of the
infection and the difficulties in microbiologic diag-
nosis. Physicians should consider NTM in evaluat-
ing patients with suspected CDI and negative aero-
bic and anaerobic cultures. Proper surveillance and
strict adherence to infection control measures can
potentially prevent NTM-related CDI. There is
a need for further research into the appropriate
choice and duration of antimicrobial therapy for
NTM-related CDI. 
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